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Abstract
Background: Improved life expectancy in high HIV prevalence populations has been
observed since antiretroviral therapy (ART) scale-up. However, it is unclear if the benefits
are sustained, and the mortality among HIV-positive individuals not (yet) on ART is not
well described. We assessed temporal change in mortality over 9 years in rural Malawi.
Methods: Within a demographic surveillance site in northern rural Malawi, we combined
demographic, HIV and ART uptake data. We calculated life expectancy using Kaplan-Meier
estimates, and compared mortality rates and rate ratios using Poisson regression, by period
of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014).
Results: Among 32664 individuals there were 1424 deaths; 1930 individuals were known
HIV-positive, of whom 1382 started ART. Overall, life expectancy at age 15 years increased
by 10 years within 5 years of ART introduction, and plateaued. Age-standardized adult
mortality rates declined from 11.3/1000 to 7.5/1000 person-years between the first and
last time period. In July 2011-June 2014 compared with July 2005–June 2008, mortality
declined in HIV-positive individuals on ART (rate ratio adjusted (aRR) for age, sex, location
and education, 0.3; 95% confidence interval (CI) 0.2–0.5) and in those not (yet) on ART
(aRR 0.3; 95%CI 0.1–0.5) but not in HIV-negative individuals (aRR 1.1; 95%CI 0.7–1.9).
Conclusions: Total population adult life expectancy increased toward that of HIV-negative
individuals by 2011 and remained raised. The reduction in all-cause and HIV-related
mortality in HIV-positive individuals not (yet) on ART suggests ART uptake is occurring at
an earlier disease stage, particularly in women.
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Introduction
In 2004, Malawi initiated a public health approach to HIV
care and treatment services. The programme aimed to de-
liver antiretroviral therapy (ART) to all eligible HIV-
positive individuals presenting to decentralized clinics,
with minimal reliance on laboratory support for determin-
ing eligibility and for monitoring patients in care.1,2 Early
success of this initiative was evident within the first year of
scale-up, with increased survival among those started on
treatment3 and declines in all-cause mortality rates at the
population level.4
Since the scale-up of ART programmes, substantial re-
ductions in adult mortality 5 and improved life expectancy
among HIV-positive individuals on ART6–9 have been
observed in other high HIV prevalence sub-Saharan
African (SSA) countries. However, the trends in all-cause
and cause-specific mortality patterns in HIV-positive indi-
viduals who are not (yet) receiving ART are not well
described. Understanding the temporal trends in these dif-
ferent groups is essential for evaluating the impact of fu-
ture test and treat strategies and establishing whether
continued improvement in mortality might be expected in
proportion to the increased burden of ART care.10,11
Although introduced nationally in 2004, ART was not
available free at the point of care in northern rural Malawi
until July 2005. Within a year, all-cause mortality had
declined by 16%4 and within the next 2 years, mortality
declined by 32%.12 In this population, deaths attributable
to HIV in adults, as assigned by verbal autopsy, decreased
from 42% in 2005 to 17% in 2009.13 It is not clear if these
early improvements in mortality are sustained beyond this
time, during a period of increasingly decentralized ART
care, and where there is little availability of CD4 cell counts
or viral load monitoring for those on long-term treatment.
This study uses population-level demographic and HIV
test data from northern rural Malawi to investigate the ef-
fect of the ART programme on life expectancy and adult
all-cause and cause-specific mortality, including HIV-
positive individuals with and without ART uptake, cover-
ing a 9-year period of scale-up of ART availability through
increasingly decentralized care.
Methods
Setting
The Karonga demographic surveillance site (DSS), was es-
tablished in 2002 in a rural population of nearly 33 000 in-
dividuals in northern Malawi, and conducts continuous
demographic surveillance, with rigorous identification pro-
cedures permitting linkage to data collected in other stud-
ies nested within the surveillance population.14
HIV counselling and testing (HCT) of the DSS popula-
tion has been conducted for various studies since 1985. In
2005–06, HIV prevalence was estimated at 11.5%15 from a
population-representative stratified sample sero-survey in
those aged 18 to 59 years. Four annual house-to-house
cross-sectional HIV sero-surveys were conducted between
September 2007 and September 2011, for all individuals
aged 15 years or older, involving counselling, enquiry about
previous HIV testing and ART uptake start date, and rapid
HIV testing with results available to participants. By 2010,
HIV prevalence had declined to 8%.16 In 2013, an add-
itional survey invited participants aged 18 years and older
who had missed earlier rounds to screen for HIV infection,
using rapid testing with results immediately available.
ART became available in Karonga District Hospital,
70 km north of the DSS area, in July 2005. Within the
DSS, ART was first available from a single rural hospital in
2006,12 then from an additional health centre in 2010 and
then from three further health centres between 2011 and
early 2012. In the wider Karonga district, there were four
ART clinics in 2008, six clinics in 2010 and 16 clinics by
the end of 2012.17 From 2005 to 2010, individuals were
eligible for ART if they were in World Health
Organization (WHO) clinical stage 3 or 4 or had a CD4
cell count< 250 cells/mm. This was extended to
CD4< 350 cells/mm3 in 2011 (and to < 500 cells/mm3 in
July 2014, after this study period). Throughout the period
of this study, CD4 cell counts were not consistently avail-
able and viral load monitoring was not available in the sur-
veillance area. Before and during ART roll-out there was a
policy to provide preventative care to all HIV-positive pa-
tients, including nutritional support, TB screening and
Key Messages
• A sustained increased adult life expectancy during a period of decentralized ART care in Malawi.
• A decline in all-cause and HIV-related mortality in HIV-positive adults on and not (yet) on ART.
• Suggests earlier uptake of ART in women than in men.
• Success of a public health approach to ART provision in Malawi.
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treatment and prophylactic cotrimoxazole antibiotics, al-
though delivery was variable.
By mid-2008, ART uptake in the DSS area was estimated
to be at least 60% of those eligible, with greater uptake
(65%) in women than in men (48%).18 In the district,
6-month retention in care increased from 70% in the first 2
years of ART availability to 92% in 2011–12.17
Data sources
Information relating to an individual’s first ART start date
was collected through interviews and linked ART records.
If conflicting data were observed between clinic register
and self-reported ART start dates, the clinic-register date
was used. Individual-level data on pre-ART care was not
available for this analysis. HIV test results were obtained
from testing conducted in population-level and clinic-
based studies between 2005 and 2014. Socio-demographic
data, including location of residence (< 1 km,1 km to
tarmac road) and highest level of education (none/primary
incomplete, primary complete, secondary incomplete, sec-
ondary complete/tertiary) were obtained from the annual
census and continuous demographic surveillance.
Cause of death (HV-related, non-HIV-related) was as-
certained from verbal autopsy data. The verbal autopsies
are conducted following all deaths in the DSS, by medical
assistants with additional training using a semi-structured
questionnaire adapted from the standard World Health
Organization questionnaire. Whenever possible, the in-
formant is a close relative of the deceased and nursed them
through their final illness, and the information is collected
approximately 2–4 weeks after the death. Each verbal aut-
opsy questionnaire is independently reviewed by two clin-
icians, and in the event of discrepancies a third reviewer
assigns the cause of death after viewing the initial two re-
views. Data on HIV status may be available to the reviewer
within the verbal autopsy questionnaire or through access
to the HIV test database, if the deceased had participated
in a study providing HIV testing. If a decision cannot be
made on the cause, the death is coded as un-specifiable. Of
all adult deaths, 9% were either unspecified or unknown.
Statistical analysis
The analysis was restricted to adults aged 15 years or
older. To assess life expectancy trends, individuals contrib-
uted exposure time during their residence in the DSS from
January 2003 (the start of demographic surveillance in the
area, including a period preceding population-level HIV
testing and ART availability), or their date of in-migration,
if later, until the earliest of 31 December 2013, death or
out-migration. Adult life expectancy was computed as the
area under the Kaplan-Meier survival curve for each calen-
dar year. It can be interpreted as the number of additional
years that an adult– here defined as 15 years old– can
expect to live under the age- and sex- specific mortality
rates that prevail in a particular year.
For all-cause and cause-specific mortality analyses, indi-
viduals contributed exposure time during their residence in
the DSS from the start of July 2005 (when ART was first
available in the district and population-representative HIV
test data were available in the DSS), or their date of
in-migration if later, until the earliest of 30 June 2014,
death or out-migration. Returning and repeat migrants
only contributed person-years while resident in the DSS
area. HIV status and ART treatment status were treated as
time-varying covariates. Person-years were classified as
HIV-negative up to 3 years after the latest HIV-negative
test unless there was an earlier positive test. Person-years
were classified as HIV-positive after a positive test. All
other periods (before the first HIV test and > 3 years after
the latest negative test) were classified as HIV status un-
known, to avoid selection bias.
For individuals who reported ART initiation at a clinic
outside the district before July 2005, only person-years
from study entry at 1 July 2005 contributed to this ana-
lysis. ART uptake in HIV-positive individuals was classi-
fied according to ever use and duration of treatment.
Individuals were categorized as ‘ever started on ART’ from
the first ART start date and as ‘not (yet) on ART’ for the
period between an HIV-positive test result and an ART
start date, if one existed, or to study exit. In those who
ever started ART, individuals were also categorized by dur-
ation of antiretroviral treatment, with early treatment
defined as less than 6 months on ART (as this has been
shown to be a high-risk period19,20) and longer-term treat-
ment defined as 6 months or longer.
Age- and sex-specific mortality rates were calculated for
three periods of ART availability/scaling-up; early (July
2005 to June 2008), mid (July 2008 to June 2011) and late
(July 2011 to June 2014), and using age categories 15–24,
25–34, 35–44, 45–54, 55–64 and 65 years or more. To ac-
count for changing age structure in the population, age-
standardized mortality rates were calculated by using the
total population during the follow-up period as the standard
population.
All-cause and cause-specific (HIV-related, non-HIV-
related) mortality rate ratios were calculated by period of
ART availability using Poisson regression. To examine
the role of factors that might affect the association be-
tween period of ART availability and risk for all-cause
and cause-specific mortality, participants were grouped
according to sex, HIV infection and ART uptake, location
of residence, age group and highest attained level of
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education, with adjustment for these factors where appro-
priate. Likelihood ratio v2 tests were used to test for dif-
ference in the risk for all-cause and cause-specific deaths
in adults over the three calendar periods. Tests for hetero-
geneity were calculated by entering a term for the inter-
action between the time period and the co-factor variable
in the logistic regression models, and the statistical signifi-
cance of the interaction terms were calculated with likeli-
hood ratio tests.
These demographic data represent an open cohort, with
mortality outcomes available for all those remaining resi-
dent in the DSS area. To understand better the extent to
which different population sub-groups (who may be at
higher risk for death) are associated with risk for departure
from the DSS, we conducted an exploratory analysis.
All calculations used Stata version 14.0 (Stata
Corporation, College Station, TX).
Ethics approval for the studies was granted by the
National Health Sciences Research Committee of Malawi
(NHSR #419, #424, #448, #968 and #1072) and the
Ethics Committee of the London School of Hygiene &
Tropical Medicine (#5081, #5067, #5214, #6126 and
#6303).
Results
After excluding 11 individuals with indeterminate HIV test
results or a single negative test after an earlier positive re-
sult, and 26 individuals with an ART start date but a later
HIV-negative test result, 14 845 men and 17 819 women
aged 15 years and older contributed a total of 161 849 per-
son years and 1424 deaths between July 2005 and June
2014. Of 1930 individuals identified as HIV-positive dur-
ing follow-up, ART uptake was established for 1382 indi-
viduals: 1192 (86%) via a clinic register link and 190
(14%) via self-report. Data on WHO stage at ART initi-
ation were available for 97% of those with a clinic register
link: initiation at WHO stage four declined from 33% in
July 2005–June 2008, to 8% in July 2008–June 2011 and
then to 7% in July 2011–June 2014 (data not shown in
table).
All-cause adult age-standardized mortality rates
declined from 11.3/1000 person-years (py) in July 2005–
June 2008, to 10.7/1000 py in July 2008–June 2011 and
then to 7.5/1000 py in July 2011–June 2014. Overall life
expectancy at age 15 increased from 42.5 (95% CI 37.5–
48.4) to 57.9 years (95% CI 53.8–62.1) in men between
2003 and 2010 and from 45.5 (95% CI 39.6–51.5) to
61.8 (95% CI 58.0–66.9) in women between 2003 and
2011, and then plateaued: attaining life expectancy com-
parable to that observed in HIV-negative men and women
(Figure 1a and b).
Age-specific mortality rates and rate ratios in men and
women in the three periods of ART availability by sex and
10-year age groups are shown in Table 1. In men and
women, mortality was lowest in those aged 15–24 years
and highest in those aged 65 years and older, with no evi-
dence for change over time. A large reduction in mortality
was observed in women aged 25 to 44 years and men aged
25 to 54 years between the early and mid-period of ART
availability. In the late period, these mortality reductions
were sustained in women and men aged 25 to 44 years but
not in men aged 45 to 54 years.
All-cause crude mortality rates and rate ratios adjusted
for sex, age group, location of residence and education are
shown in Table 2. After adjusting for other factors there
was a 30% reduction in mortality in the adult population
between the early and mid-period of ART availability,
which was sustained during the late period. Mortality rates
were similar in men and women in the early period but a
greater reduction was observed in women (30%) than men
(20%), although there was no evidence for heterogeneity
in the association by sex (P-heterogeneity¼0.4). The fall
was sustained in both sexes in the late period (July 2011 to
June 2014).
Large reductions in mortality were observed in
HIV-positive individuals on ART, with crude mortality
(CMR) falling from 69.7/1000 py in July 2005–June 2008
to 35.6/1000 py in July 2008–June 2011 to 22.1/1000 py in
July 2011–June 2014. A large fall in mortality was observed
in HIV-positive individuals not (yet) on ART between the
early and middle period (CMR 51.3 vs 12.1/1000 py; aRR
0.2; 95% CI: 0.1–0.4) that was sustained in the late period.
Among those who started ART, mortality in the early stages
of ART treatment (< 6 months) declined over time from
149.4/1000 py in the early period, to 105.2/1000 py in the
middle period and then to 52.0/1000 py in the late period
(P¼ 0.01). There was no evidence for a decline in mortality
in those on longer-term treatment (> 6months) (P¼ 0.2), or
in HIV-negative (P¼ 0.9) or HIV-unknown individuals
(P¼ 0.2) over the study period, although mortality re-
mained lowest in HIV-negative individuals.
In HIV-positive individuals not (yet) on ART, mortality
was higher in women than men in the early period of ART
availability and greater mortality reductions were observed
in women than in men (53.3 to 13.2 per 1000 py in women
vs 48.1 to 19.6 per 1000 py in men), although there was
no evidence that the association differed by sex (P-hetero-
geneity¼ 0.5). Mortality was higher among HIV-positive
individuals not on ART and living close to a tarmac road
during the early period of ART availability compared with
those living further away; however, those close to the tar-
mac road experienced a greater decline in mortality be-
tween the early and late period than those living further
482 International Journal of Epidemiology, 2017, Vol. 46, No. 2
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away (69.5 to 13.5/1000 py vs 28.8 to 19.1/1000 py
(Table 2). Figure 2a-c shows declining mortality in men
and women in the total adult population (Figure 2a) and in
HIV-positive individuals (Figure 2b), including men and
women not (yet) on ART (Figure 2c).
Table 3 shows that HIV-related mortality in adults
declined by 70% between the early and late period of ART
availability (CMR 3.4 vs 1.2/1000 py; aRR 0.3; 95% CI:
0. 2–0.4), evident in both men and women (P< 0.001).
Mortality due to HIV-related causes declined progressively
in HIV-positive individuals on treatment, with a 70%
lower rate of HIV-related deaths in the late ART period
compared with the early period (58.4 vs 17.0 per 1000 py;
P< 0.001). Large declines in HIV-related deaths were also
observed in HIV-positive individuals not (yet) on
ART (70%). In those who ever started ART, early mortal-
ity (< 6 months on treatment) due to HIV-related causes
dropped from 130.8/1000 py to 54.3/1000 py and then to
45.5/1000 py over the three time periods (P¼ 0.02).
In this adult population there was no evidence for a de-
cline in non-HIV-related mortality between the early and
late time periods of ART availability (Table 4; 6.7 vs 5.6/
1000 py; aRR 0.9; 95% CI 0. 8–1.0; P¼ 0.2), and with no
evidence for difference between men and women (P-het-
erogeneity¼ 0.4). Between the early and late periods, a
large drop in non-HIV-related mortality was observed in
HIV-positive individuals not (yet) on treatment (18.0 vs
3.8 per 1000 py; aRR 0.2; 95% CI 0.1–0.6; P¼ 0.02) that
was not seen in HIV-positive individuals on ART, HIV-
negative or HIV-unknown individuals.
Out-migration from the study population was associated
with unknown HIV status (aRR HIV unknown vs HIV-
negative 2.0; 95% CI 1.9–2.1); with being younger (aRR 15–
24 vs 65 years or older 8.1; 95% CI 7.2–9.2); with female
sex (aRR female vs male 1.2; 95% CI 1.2–1.3), and; with
higher educational attainment (aRR secondary vs none/in-
complete primary 4.2; 95% CI 3.6–4.8; results not shown in
a table), after controlling for potential confounders.
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Figure 1. Life expectancy at 15 years in women (a) and men (b): 2003-2013.
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Discussion
Our data show that total population adult life expectancy
at age 15 in rural northern Malawi increased by almost 10
years between 2005 and 2011 and then plateaued, reach-
ing the life expectancy estimate of HIV-negative
individuals. Our results are of a similar or greater magni-
tude to the increases in mean length of life observed else-
where in high HIV prevalence sub Saharan Africa where
national ART programmes exist.7,21 In our population, the
observed increase in adult life expectancy is largely a result
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Table 1. Age specific mortality rates for adults 15 years and older by sex and period of ART availability
Person-
years
Deaths Rate/1000 py 95% CI Crude
mortality
rate ratio
95% CI Adjusted
mortality
rate ratioa
95% CI P-valueb
Male, age, years
15–24
Jul 05–Jun 08 8940 14 1.6 0.9–2.6 1.0 1.0
Jul 08–Jun 11 8910 14 1.6 0.9–2.7 1.0 0.5–2.1 1.1 0.5–2.2
Jul 11–Jun 14 9968 18 1.8 1.1–2.9 1.2 0.6–2.3 1.2 0.6–2.3 0.9
25–34
Jul 05–Jun 08 6220 46 7.4 5.5–9.9 1.0 1.0
Jul 08–Jun 11 6316 24 3.8 2.5–5.7 0.5 0.3–0.8 0.5 0.3–0.9
Jul 11–Jun 14 6534 25 3.8 2.6–5.7 0.5 0.3–0.8 0.5 0.3–0.9 0.01
35–44
Jul 05–Jun 08 3521 58 16.5 12.7–21.3 1.0 1
Jul 08–Jun 11 3968 33 8.3 5.9–11.7 0.5 0.3–0.8 0.5 0.3–0.8
Jul 11–Jun 14 4520 47 10.4 7.8–13.8 0.6 0.4–0.9 0.6 0.4–0.9 0.004
45–54
Jul 05–Jun 08 2006 41 20.4 15.1–27.8 1.0 1.0
Jul 08–Jun 11 2311 19 8.2 5.2–12.9 0.4 0.2–0.7 0.4 0.2–0.7
Jul 11–Jun 14 2630 35 13.3 9.6–18.5 0.7 0.4–1.0 0.7 0.4–1.1 0.004
55–64
Jul 05–Jun 08 1319 32 24.3 17.2–34.3 1.0 1.0
Jul 08–Jun 11 1347 27 20.0 13.7–29.2 0.8 0.5–1.4 0.9 0.5–1.4
Jul 11–Jun 14 1475 19 12.9 8.2–20.2 0.5 0.3–0.9 0.6 0.3–1.0 0.1
65þ
Jul 05–Jun 08 1698 75 44.2 35.2–55.4 1.0 1.0
Jul 08–Jun 11 1739 94 54.0 44.1–66.1 1.2 0.9–1.7 1.3 1.0–1.8
Jul 11–Jun 14 1855 75 40.4 32.2–50.7 0.9 0.7–1.3 1.0 0.7–1.4 0.2
Female, age, years
15–24
Jul 05–Jun 08 9356 13 1.4 0.8–2.4 1.0 1.0
Jul 08–Jun 11 9477 15 1.6 1.0–2.6 1.1 0.5–2.4 1.3 0.6–2.8
Jul 11–Jun 14 10698 18 1.7 1.1–2.7 1.2 0.6–2.5 1.4 0.7–2.9 0.6
25–34
Jul 05–Jun 08 6894 64 9.3 7.3–11.9 1.0 1
Jul 08–Jun 11 7298 23 3.2 2.1–4.7 0.3 0.2–0.5 0.3 0.2–0.6
Jul 11–Jun 14 7802 21 2.7 1.8–4.1 0.3 0.2–0.5 0.3 0.2–0.5 < 0.001
35–44
Jul 05–Jun 08 3933 42 10.7 7.9–14.5 1.0 1.0
Jul 08–Jun 11 4359 24 5.5 3.7–8.2 0.5 0.3–0.9 0.5 0.3–0.9
Jul 11–Jun 14 5156 19 3.7 2.4–5.8 0.3 0.2–0.6 0.4 0.2–0.6 0.001
45–54
Jul 05–Jun 08 2640 30 11.4 7.9–16.3 1.0 1.0
Jul 08–Jun 11 2860 22 7.7 5.1–11.7 0.7 0.4–1.2 0.7 0.4–1.2
Jul 11–Jun 14 3149 24 7.6 5.1–11.4 0.7 0.4–1.1 0.7 0.4–1.2 0.3
55–64
Jul 05–Jun 08 1791 34 19.0 13.6–26.6 1.0 1.0
Jul 08–Jun 11 1929 20 10.4 6.7–16.1 0.5 0.3–0.9 0.6 0.3–1.0
Jul 11–Jun 14 2043 22 10.8 7.1–16.4 0.6 0.3–1.0 0.6 0.3–1.0 0.1
65þ
Jul 05–Jun 08 2254 118 52.4 43.7–62.7 1.0 1.0
Jul 08–Jun 11 2342 102 43.5 35.9–52.9 0.8 0.6–1.1 0.8 0.6–1.1
Jul 11–Jun 14 2591 117 45.2 37.7–54.1 0.9 0.7–1.1 0.9 0.7–1.1 0.4
py, person-years; June, June; Jul, July; -, range.
aAdjustment made for location of residence (< 1 km, 1 km from roadside), education (none/incomplete primary, complete primary, incomplete secondary,
complete secondary/tertiary, unknown), where appropriate.
bP-value test for difference in the association between time-period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014)
and mortality, calculated with a likelihood ratio test.
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of the decline in adult mortality of HIV-positive individ-
uals during a 9-year period of ART scale-up, decentralized
care and annual household-level HIV testing, with almost
universal acceptance of test results.16,22
The large reductions in all-cause and HIV-related mor-
tality over time in those not (yet) on ART indicates a shift
in ART initiation, from late-stage AIDS to an earlier phase
of infection, getting HIV-positive individuals onto treat-
ment early, leaving only relatively healthy positive individ-
uals without (or yet to start) treatment. The sustained
reduction in mortality over time in HIV-positive individ-
uals and reduction in HIV-related mortality are consistent
with our earlier findings13 and confirm that the early suc-
cess of the ART programme12 has continued over the
Table 3. HIV-related mortality for adults 15 years and older by period of ART availability and HIV infection/ART use
Person-
years
HIV-
related
deaths
Rate/1000 py 95% CI Crude
mortality
rate ratio
95% CI Adjusted
mortality
rate ratioa
95% CI Adjusted
mortality
rate ratiob
95% CI P-valuec
Overall population
Period of ART
Jul 05–Jun 08 50571 174 3.4 3.0–4.0 1.0 1.0 1.0
Jul 08–Jun 11 52857 73 1.4 1.1–1.7 0.4 0.3–0 .5 0.4 0.3–0.5 0.4 0.3–0.5
Jul 11–Jun 14 58421 69 1.2 0.9–1.5 0.3 0.3–0.5 0.3 0.2–0.4 0.3 0.2–0.4 < 0.001
Sex
Male
Jul 05–Jun 08 23703 91 3.8 3.1–4.7 1.0 1.0 1.0
Jul 08–Jun 11 24592 37 1.5 1.1–2.1 0.4 0.3–0.6 0.4 0.3–0.5 0.4 0.3–0.5
Jul 11–Jun 14 26981 35 1.3 0.9–1.8 0.3 0.2–0.5 0.3 0.2–0.5 0.3 0.2–0.5 < 0.001
Female
Jul 05–Jun 08 26868 83 3.1 2.5–3.8 1.0 1.0 1.0
Jul 08–Jun 11 28266 36 1.3 0.9–1.8 0.4 0.3–0.6 0.4 0.3–0.6 0.4 0.3–0.6
Jul 11–Dec13 31439 34 1.1 0.8–1.5 0.4 0.2–0.5 0.3 0.2–0.5 0.3 0.2–0.5 < 0.001
HIV infection/ART use by period of ART
HIV-positive; ever on ART
Jul 05–Jun 08 531 31 58.4 41.0–83.0 1.0 1.0 1.0
Jul 08–Jun 11 1771 51 38.8 21.9–37.9 0.5 0.3–0.8 0.5 0.3–0.7 0.5 0.3–0.7
Jul 11–Jun 14 2710 46 17.0 12.7–22.7 0.3 0.2–0.5 0.3 0.2–0.4 0.3 0.2–0.4 < 0.001
HIV-positive; not (yet) on ART
Jul 05–Jun 08 390 12 30.8 17.5–54.2 1.0 1.0 1.0
Jul 08–Jun 11 1485 9 6.1 3.2–11.7 0.2 0.1– 0.5 0.2 0.1–0.5 0.2 0.1–0.5
Jul 11–Jun 14 1064 11 10.3 5.7–18.7 0.3 0.1– 0.8 0.3 0.1–0.7 0.3 0.1–0.7 0.001
HIV status unknown
Jul 05–Jun 08 44742 131 2.9 2.5–3.5 1.0 1.0 1.0
Jul 08–Jun 11 14523 12 0.8 0.5–1.5 0.3 0.2–0.5 0.3 0.2–0.5 0.3 0.1–0.5
Jul 11–Jun 14 21947 12 0.5 0.3–1.0 0.2 0.1–0.3 0.2 0.1–0.4 0.2 0.1–0.3 < 0.001
HIV-positive ever on ARTd
HIV test positive; < 6 months on treatment
Jul 05–Jun 08 161 21 130.8 85.3–200.5 1.0 1.0 1.0
Jul 08–Jun 11 238 20 54.3 54.3–130.5 0.6 0.3–1.2 0.6 0.3–1.1 0.6 0.3–1.2
Jul 11–Jun 14 154 7 45.5 20.7–95.4 0.3 0.1–0.8 0.3 0.1–0.8 0.3 0.1–0.7 0.02
HIV test positive;  6 months on treatment
Jul 05–Jun 08 371 10 27.0 14.5–50.2 1.0 1.0 1.0
Jul 08–Jun 11 1533 31 20.2 14.2–28.7 0.7 0.4–1.5 0.7 0.4–1.5 0.70 0.4–1.5
Jul 11–Jun 14 2556 39 15.3 11.1–20.9 0.6 0.3–1.1 0.5 0.3–1.1 0.50 0.3–1.1 0.2
Jun, June; Jul, July; py, person-years; -, range.
aAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65þ years), sex (male, female), where appropriate.
bAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65þ years), sex (male, female), location of residence (< 1 km, 1 km from roadside), educa-
tion (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.
cP-value test for difference in the association between period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and
mortality, calculated with a likelihood ratio test.
dIn those who used ART during follow-up, the data are presented by duration of treatment (< 6 and  6 months).
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longer term in this rural, resource-constrained setting.
However, our results suggest that smaller gains are being
made in men than in women, particularly among those
who are HIV-positive and yet to start ART. These findings
indicate that men with a positive HIV diagnosis are re-
maining, to a greater extent than women, without treat-
ment until too late into the disease: a finding consistent
with other studies from sub-Saharan Africa.23 In our
Table 4. Non-HIV-related mortality for adults 15 years and older by period of ART availability and HIV infection/ART use
Person-years Non-HIV-related
deaths
Rate/1000 py 95% CI Crude
mortality
rate ratio
95% CI Adjusted
mortality
rate ratioa
95% CI Adjusted
mortality
rate ratiob
95% CI P-valuec
Overall population
Period of ART
Jul 05–Jun 08 50571 341 6.7 6.1–7.5 1.0 1.0 1.0
Jul 08–Jun 11 52857 313 5.9 5.3–6.6- 0.9 0.8–1.0 0.9 0.8–1.0 0.9 0.8–1.1
Jul 11–Jun 14 58421 325 5.6 5.0–6.2- 0.8 0.7–1.0 0.8 0.7–1.0 0.9 0.8–1.0 0.2
Sex
Male
Jul 05–Jun 08 23703 154 6.5 5.5–7.6- 1.0 1.0 1.0
Jul 08–Jun 11 24592 158 6.4 5.5–7.5- 1.0 0.8–1.2 1.0 0.8–1.2 1.03 0.8–1.3
Jul 11–Jun 14 26981 163 6.0 5.2–7.0- 0.9 0.7–1.2 0.9 0.7–1.2 1.00 0.8–1.2 1.00
Female
Jul 05–Jun 08 26868 187 7.0 6.0–8.0- 1.0 1.0 1.0
Jul 08–Jun 11 28266 155 5.5 4.7–6.4- 0.8 0.6–1.0 0.8 0.6–1.0 0.8 0.7–1.0
Jul 11–Jun 14 31439 162 5.2 4.4–6.0- 0.7 0.6–0.9 0.7 0.6–0.9 0.8 0.6–1.0 0.04
HIV infection/ART use by period of ART
HIV-negative 4876 15 3.1 1.9–5.1- 1.0 1.0 1.0
Jul 05–Jun 08 35080 157 4.5 3.8–5.2- 1.5 0.9–2.5 1.1 0.7–1.9 1.1 0.7–1.9
Jul 08–Jun 11 32700 149 4.6 3.9–5.4 1.5 0.9–2.5 1.2 0.7–2.0 1.2 0.7–2.0 0.8
Jul 11–Jun 14
HIV-positive; ever on ART
Jul 05–Jun 08 531 6 11.3 5.1–25.1 1.0 1.0 1.0
Jul 08–Jun 11 1771 11 6.2 3.4–11.2 0.5 0.2–1.5 0.5 0.2–1.3 0.5 0.2–1.3
Jul 11–Jun 14 2710 12 4.4 2.5–7.8 0.4 0.1–1.0 0.4 0.1–1.0 0.3 0.1–0.9 0.1
HIV-positive; not (yet) on ART
Jul 05–Jun 08 390 7 18.0 8.6–37.7- 1.0 1.0 1.0
Jul 08–Jun 11 1484 9 6.1 3.2–11.7 0.3 0.1–0.9 0.3 0.1–0.8 0.3 0.1–0.8
Jul 11–Jun 14 1064 4 3.8 1.4–10.0 0.2 0.1–0.7 0.2 0.1– 0.6 0.2 0.1–0.6 0.02
HIV status unknown
Jul 05–Jun 08 44774 313 7.0 6.3–7.8- 1.0 1.0 1.0
Jul 08–Jun 11 14523 136 9.4 7.9–11.1 1.3 1.1–1.6 1.2 1.0–1.5 1.2 1.0–1.5
Jul 11–Jun 14 21947 160 7.3 6.2–8.5- 1.0 0.9–1.3 1.0 0.8–1.2 1.1 0.9–1.3 0.10
HIV-positive ever on ARTd
HIV test positive; < 6 months on treatment
Jul 05–Jun 08 161 3 18.7 6.0–54.5- 1.0 1.0 1.0
Jul 08–Jun 11 238 4 16.8 6.4–45.3 0.9 0.2–4.0 0.9 0.2–3.9 0.9 0.2–4.1
Jul 11–Jun 14 154 1 6.5 1.0–50.4- 0.3 0.04–3.3 0.3 0.04–3.3 0.3 0.04–3.3 0.6
HIV test positive;  6 months on treatment
Jul 05–Jun 08 371 3 8.1 2.6–25.1 1.0 1.0 1.0
Jul 08–Jun 11 1533 7 4.6 2.2–9.6 0.6 0.1–2.2 0.4 0.1–1.7 0.4 0.1–1.7
Jul 11–Jun 14 2556 11 4.3 2.4–7.8 0.5 0.1–1.9 0.4 0.1–1.6 0.4 0.1–1.5 0.5
Jun, June; Jul, July; py, person-years; -, range.
aAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65þ years), sex (male, female), where appropriate.
bAdjustment made for age (15–24, 25–34, 35–44, 45–54, 55–64, 65þ years), sex (male, female), location of residence (< 1 km, 1 km from roadside), educa-
tion (none/incomplete primary, complete primary, incomplete secondary, complete secondary/tertiary, unknown), where appropriate.
cP-value test for difference in the association between period of ART availability (July 2005–June 2008, July 2008–June 2011 and July 2011–June 2014) and
mortality, calculated with a likelihood ratio test.
cIn those who used ART during follow-up, the data are presented by duration of treatment (< 6 and  6 months).
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setting, the late treatment occurred even though the indi-
viduals were aware of their HIV status, an issue that may
be important to consider as the global impetus for achiev-
ing 90-90-90 targets intensifies, requiring initiation of
ART immediately after testing HIV positive.10,11
Among HIV-positive individuals, the initially high mor-
tality in the first 6 months of treatment more than halved
over time as individuals moved onto treatment at an earlier
stage of disease (evidenced by 7% initiating ART in WHO
stage 4 in the late phase, compared with 33% in the early
phase); but it remained a high-risk period, as observed else-
where.24 The large decline in HIV-related deaths in those
of unknown HIV status suggests that few undiagnosed
HIV-positive individuals remain in the surveillance popula-
tion, following high participation rates in multiple HIV
sero-surveys, during which 95% received their results.16
Access difficulties, including distance to clinics and trans-
port costs, are established barriers for linkage to and reten-
tion in care.25 In Malawi, decentralization of ART services
is associated with improved retention of patients in care.17
However, lower declines in all-cause and HIV-related mor-
tality were observed in those living in more rural areas
compared with those living close to a tarmac road, which
may suggest more unmet need peripherally despite
decentralization.
Our study linked annual sero-survey HIV test results
and ART clinic data from across the surveillance popula-
tion, which facilitated categorization of individuals accord-
ing to HIV status and ART uptake to investigate in detail
the impact of ART on mortality over time. However, our
data include a relatively small HIV-positive adult popula-
tion, so the confidence intervals on our mortality estimates
are wide, particularly for age-group categories and other
sub-group analyses. Nonetheless, HIV testing was provided
in the community to a population representative sample be-
tween 2005 and 2006 and across all adults (15 years and
older) between 2007 and 2011, so selection bias should not
be a major concern for our study. HIV-unknown individ-
uals contributed the largest proportion of person-years in
the early phase of ART availability but, since HIV testing
across the entire population did not start until 2007, the un-
known population is likely to be representative of the over-
all population. Inclusion of undiagnosed, late-stage HIV-
positive individuals in the HIV-unknown group will have
contributed to the higher HIV-related mortality in the early
period compared with the late period, when fewer chronic-
ally undiagnosed HIV-positive individuals remain in the
population. Adults of unknown HIV status, young individ-
uals, women and those with higher educational attainment
were most at risk of out-migration from the DSS. Data on
the health status of out-migrants at the time of departure
(or their subsequent survival or death) were not available,
so the extent to which their departure affected our mortal-
ity and life expectancy estimates could not be determined.
However, in other settings where tracking of out-migrants
has been implemented, higher mortality in those individuals
has been reported,(26) so it is possible that our results (and
those from other DSS and open cohort studies) somewhat
underestimate mortality and overestimate life expectancy
gains. It is also possible that compared with the general
population, higher life expectancy gains were observed in
our surveillance population where health-related research
has been conducted for many years. We have previously
shown that during this time period, an increasing propor-
tion of verbal autopsy informants reported that they knew
the deceased’s HIV status, and the HIV status recorded on
the verbal autopsy report influences the way the clinician
reviewer assigns cause of death irrespective of symptoms.27
Hence it is possible that our findings underestimate to some
extent the true gains in HIV-related mortality although,
given the stable estimates of non-HIV-related mortality,
misclassification is unlikely to be a major issue.
As the numbers of infected individuals surviving on
ART increase; long-term retention and adherence; onward
transmission from those who have interrupted treatment;
and, identification of virological failure in long-term ART
users, will be a challenge for the current public health pro-
gramme and require ongoing monitoring and evaluation.
In 2011, Malawi expanded the criteria for ART eligibility
to include HIV-positive individuals with CD4 counts<350
cell/mm3, and initiation of life-long treatment in pregnant
and breastfeeding women irrespective of disease severity,28
and to HIV-positive individuals with CD4 counts<500/
mm3 from July 2014 onwards.29 These changes facilitate
earlier initiation and increase the numbers of individuals
alive on ART, but the sustained gains in adult life expect-
ancy depend on continued access to effective treatment and
high levels of retention and adherence of those in care.
With a growing number of individuals surviving on ART,
early identification of virological failure with the option to
switch treatment at decentralized clinics is needed but will
be a challenge in this setting
Conclusions
Our results suggest that large reductions in adult mortality
and increasing adult life expectancy have been achieved in
rural -Malawi over a 9-year period of ART availability, as
HIV infected individuals move into care at an earlier stage
of disease. HIV-positive men may be more likely than
women to remain without ART until a late stage of disease.
These data confirm that the success achieved in the early
phase of ART availability has continued, highlighting the
success of the public health approach to HIV care in
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Malawi. Improvement in mortality was observed in those
who have accessed care and also in those not yet in care.
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